Global Vaccine Contract Manufacturing Market 2019-2030 by Service Portfolio, Expression System Used, Scale of Operation, Size of Manufacturers, Geography

News provided by

Aug 08, 2019, 09:15 ET

DUBLIN, Aug. 8, 2019 /PRNewswire/ -- The "Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Vaccine Contract Manufacturing Market (2nd Edition), 2019 - 2030 report features an extensive study on contract service providers engaged in the development and manufacturing of vaccines. The study features in-depth analyses, highlighting the capabilities of various vaccine CMOs.

The global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. According to the WHO, the global vaccination rate is nearly 85%, demonstrating the high clinical demand for vaccines. In addition to meeting the growing demand for vaccines, the developers of these pharmacological interventions are also plagued by high costs of development and complex production protocols. Given that vaccine manufacturing requires highly regulated, state-of-the-art technologies, it has become increasingly difficult for stakeholders to establish in-house expertise for large-scale manufacturing of vaccines.

As a result, vaccine developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical development and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

One of the key objectives of the report was to estimate the future size of the market. Based on the parameters, such as the growth of the overall vaccine market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2019-2030.

In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced vaccine-related operations (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings) [B] types of expression systems (mammalian, microbial and others), [C] size of contract service provider company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Classification of Vaccines based on the Type of Active Ingredient
3.3. Key Components within Vaccine Formulations
3.4. Vaccine Development and Manufacturing
3.5. Vaccine Contract Manufacturing

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Vaccine Contract Manufacturers: Overall Market Landscape

5. COMPANY COMPETITIVE ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Input Parameters
5.4. Competitiveness Analysis: Vaccine Contract Manufacturers in North America
5.5. Competitiveness Analysis: Vaccine Contract Manufacturers in Europe
5.6. Competitiveness Analysis: Vaccine Contract Manufacturers in Asia-Pacific and Rest of the World

6. VACCINE CONTRACT MANUFACTURING IN NORTH AMERICA
6.1. Chapter Overview
6.2. Albany Molecular Research (AMRI) / OSO BioPharmaceuticals Manufacturing (OsoBio)
6.3. Catalent Biologics
6.4. Charles River Laboratories
6.5. Meridian Life Science (MLS)
6.6. BioReliance (A Unit of Merck)

7. VACCINE CONTRACT MANUFACTURING IN EUROPE
7.1. Chapter Overview
7.2. Cobra Biologics
7.3. Eurogentec
7.4. IDT Biologika
7.6. Lonza

8. VACCINE CONTRACT MANUFACTURING IN ASIA PACIFIC AND THE REST OF THE WORLD
8.1. Chapter Overview
8.2. GreenPak Biotech
8.3. Hong Kong Institute of Biotechnology
8.4. WuXi AppTec ((WuXi Biologics)
8.5. Bharat Biotech
8.6. Biological E

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Vaccine Contract Manufacturing: List of Partnerships and Collaborations

10. RECENT EXPANSIONS
10.1. Chapter Overview

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Vaccine Contract Manufacturing Market: Global Production Capacity (in Liters) 11.3.1.
11.4. Conclusion

12. DEMAND ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Global Clinical Demand for Vaccines: Analysis by Number of Trials
12.4. Global Clinical Demand for Vaccines: Analysis by Enrolled Patient Population
12.5. Global Clinical Demand for Vaccines: Annual Demand of Vaccines
12.6. Concluding Remarks

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Vaccine Contract Manufacturing Market, 2019-2030
13.4. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Service Portfolio
13.5. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Expression System Used
13.6. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
13.7. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers
13.8. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Geography

14. SWOT ANALYSIS
14.1 Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Comparison of Swot Factors
14.7. Concluding Remarks

15. FUTURE TRENDS
15.1. Chapter Overview
15.2. Adoption of Innovative Technologies to Drive Growth
15.3. Shift to Single-Use Systems and Components
15.4. The Advent of Virus-like Particles (VLPs)
15.5. Growing Investments in Existing Infrastructure
15.6. Evolving Client / Sponsor and CMO / CDMO Relationships
15.7. Business Acquisition and Consolidation Activity

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Batavia Biosciences
16.2.1 Company Snapshot
16.2.2 Interview Transcript: Menzo Havenga, CEO and Claire Otjes, Marketing Manager
16.3. Goodwin Biotechnology
16.3.2 Interview Transcript: David C Cunningham, Director Of Corporate Development
16.4. Statens Serum Institut
16.4.2 Interview Transcript: Ingrid Cromann, Director - Vaccine Development
16.5. Novasep Synthesis
16.5.2 Interview Transcript: Kevin Daley, Director Pharmaceuticals
16.6. ProBioGen
16.6.2 Interview Transcript: Oliver Schub, Senior Business Development Manager
16.7. Wacker Biotech
16.7.1 Company Snapshot
16.7.2 Interview Transcript: Sebastian Schuck, Head of Business Development

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

3P Biopharmaceuticals
Acambis
Accugenix
Actavis
Advanced BioScience Laboratories
Advaxis
Aeras
AGC Biologics
AJ Biologics
Albany Molecular Research
Alexion Pharmaceuticals
Algonomics
Altaris Capital Partners
AmbioPharm
AnaSpec
Aptuit
Association for Assessment and Accreditation of Laboratory Animal Care
Avid Bioservices
Bachem
Batavia Biosciences
Battelle
Bavarian Nordic
Baxter BioPharma Solutions
Baylor Institute for Immunology Research
BD Biosciences
Benchmark Vaccines
Bharat Biotech
Bill & Melinda Gates Foundation
Bilthoven Biologicals
Biocell
Biocon
BioConnections
BioConvergence
Biofabri
Bioline
Biological E
BioMARC
Biomay
Biomedical Advanced Research and Development Authority
BioMotiv
BiondVax Pharmaceuticals
BioReliance
BioTechnique
Biotechnology and Biological Sciences Research Council
Biovest International
Birgi Mefar Group
Boehringer Ingelheim
Boston Children's Hospital
Bristol-Myers Squibb
Bryllan
CALIXAR
Canadian Animal Health Institute
Canadian Council on Animal Care
Catalent
Celsis International
Cetus
CEVEC Pharmaceuticals
Charles River Biopharmaceutical Services
Charles River Laboratories
Chimera Biotec
China Agricultural University
China National Biotec Group
Chinese Center for Disease Control and Prevention
Chinese University of Hong Kong
Chiron Behring Vaccines (acquired by Bharat Biotech)
Cobra Biologics
Cook Pharmica
Crucell Sweden
Cytovance Biologics
Daiichi Sankyo
Deltamune
Dr. Reddy's Laboratories
Dyadic International
EGYVAC
Emergent BioSolutions
Engineering and Physical Sciences Research Council
EuBiologics
Eurogentec
European Medicines Agency
ExpreS2ion Biotech Holding
Exxell BIO
Federation of Indian Chambers of Commerce and Industry
Florida Biologix
French National Agency for Research on AIDS and Viral Hepatitis
Friedrich-Loeffler-Institut
FUJIFILM Diosynth Biotechnologies
Gallant Custom Laboratories
Gamma Vaccines
GAVI
Genentech
GENEWIZ
Genzyme Polyclonals
GlaxoSmithKline
GNH India Pharmaceuticals
Goodwin Biotechnology
Grand River Aseptic Manufacturing
Greenpak Biotech
Grifols
Guangxi Veterinary Research Institute
Guangzhou Air force Hospital
Haffkine Institute
HALIX
Harbin Veterinary Research Institute
Hennepin Healthcare Research Institute
HLL Biotech
Hong Kong Institute of Biotechnology
IDT Biologika
ImevaX
Immune Design
Immune Targeting Systems
ImmunoSite Technologies
ImVisioN Therapeutics
Index Ventures
Indian Council of Medical Research
Indian Immunologicals
Infectious Disease Research Institute
Innovate UK
Integrity Bio
International Medica Foundation
International Society for Pharmaceutical Engineering
Interros
Intervacc
Inviragen
Irvine Pharmaceutical Services
Israel Institute for Biological Research
Jubilant HollisterStier
KABS Pharmaceutical Services
Kalon Biotherapeutics
Kaneka
KBI Biopharma
LigoCyte Pharmaceuticals
Lonza
Luina Bio
Magellan BioScience Group
MassBiologics
Medicago
Medicines and Healthcare products Regulatory Agency
Merck
Meridian Life Science
Mitsubishi Gas Chemical
Mitsubishi Tanabe Pharma
Moderna Therapeutics
Mymetics
Najt Technologies
National Avian Influenza Reference Laboratory
National Heart, Lung, and Blood Institute
National Institutes of Allergy and Infectious Diseases
NewLink Genetics
Norwegian Institute of Public Health
Nouscom
Novartis
Novasep
Novavax
NPO Petrovax Pharm
OctoPlus
Okairos
Oncotest
Organization for Economic Cooperation and Development
OSO BioPharmaceuticals Manufacturing
Pacific GMP
Panacea Biotec
Paragon Bioservices
PATH
PaxVax
Pfenex
Pfizer
Pfizer CentreOne
PharmaPak
PharmaSynth
Premas Biotech
Prime European Therapeuticals
ProBioGen
Protagen
PX'Therapeutics
QuiaPEG Pharmaceuticals
RAFAGEN
Recipharm
Richter-Helm
RIEMSER Pharma
SAFC
Sanofi Active Ingredient Solutions
Sanofi Pasteur
Sartorius Stedim Biotech
Serum Institute of India
Shandong Zhaoxin Bio-tech
Shanghai Laboratory Animal Center
ShangPharma Innovation
SialoCarb
Sichuan Agricultural University
Sigma-Aldrich
SK Chemicals
Soligenix
South China Agricultural University
State Secretariat for Education, Research and Innovation
Statens Serum Institut
Stellar Biotechnologies
Sumagen
SynCo Bio Partners
Synthelis
Takeda Pharmaceuticals
Temasek Life Sciences Ventures
The Hong Kong Jockey Club Charities Trust
Thermo Fisher Scientific
Thomas Jefferson University
Tianjin CanSino Biotechnology
Transgene
Unitech Pharma Group
United States Army Medical Research Institute of Infectious Diseases
Univercells
University of Copenhagen
University of Maryland
University of Oxford
University of Pennsylvania
Upperton Pharma Solutions
Vaccibody
VACSERA
Valerius Biopharma
Valneva
Vaxin
Vetter Pharma
VGXI
Vibalogics
Vivalis
Vybion
Waisman Biomanufacturing
Walter Reed Army Institute of Research
Wellcome Trust
WIL Research
World Trade Organization
WuXi AppTec
Wuxi Fortune Pharmaceutical
Zoetis

For more information about this report visit https://www.researchandmarkets.com/r/obrfhq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets